[Apoptosis and tumor regression in locally advanced non-small cell lung cancer with neoadjuvant therapy]
- PMID: 12739056
- DOI: 10.1007/s00292-002-0607-4
[Apoptosis and tumor regression in locally advanced non-small cell lung cancer with neoadjuvant therapy]
Abstract
Dysregulation of apoptosis is closely associated with malignant cell transformation. On the other hand, apoptosis is induced by chemotherapy or irradiation. Therefore, in 54 patients with locally advanced non-small cell lung cancer (NSCLC, 36 squamous cell carcinomas, 18 adenocarcinomas, stage IIIA/IIIB), apoptotic indices were comparatively analysed before onset and after termination of neoadjuvant therapy. The results were compared with the response to neoadjuvant therapy (extent of therapy-induced tumour regression) as well as the survival times. A statistically significant difference could not be established between pre-therapeutically and post-surgically established apoptotic indices (mean values: 0.93% vs. 1.1%). Neither before therapy nor after surgery did the apoptotic indices show a significant predictive value concerning different overall survival times. These results suggest that neoadjuvant therapy does not modify the extent of apoptosis in lung cancer in the long term. Only a few weeks after the completion of the neoadjuvant chemoradiotherapy this contributes to a net proliferation of the residual tumour tissue which is largely equivalent to that of the untreated tumour.
Similar articles
-
Influence of apoptosis and cell cycle regulator proteins on chemotherapy response and survival in stage IIIA/IIIB NSCLC patients.J Thorac Oncol. 2007 Apr;2(4):293-8. doi: 10.1097/01.JTO.0000263711.54073.fa. J Thorac Oncol. 2007. PMID: 17409800
-
Multicenter phase II study evaluating docetaxel and cisplatin as neoadjuvant induction regimen prior to surgery or radiochemotherapy with docetaxel, followed by adjuvant docetaxel therapy in chemonaive patients with NSCLC stage II, IIIA and IIIB (TAX-AT 1.203 Trial).Lung Cancer. 2014 Sep;85(3):395-400. doi: 10.1016/j.lungcan.2014.06.019. Epub 2014 Jul 3. Lung Cancer. 2014. PMID: 25043642 Clinical Trial.
-
Histologic assessment of non-small cell lung carcinoma after neoadjuvant therapy.Mod Pathol. 2003 Nov;16(11):1102-8. doi: 10.1097/01.MP.0000096041.13859.AB. Mod Pathol. 2003. PMID: 14614049
-
[Neoadjuvant chemotherapy and chemoradiotherapy in locally advanced stage IIIA and IIIB of non-small-cell bronchial carcinoma (the Essen concept)].Praxis (Bern 1994). 1997 Oct 15;86(42):1647-53. Praxis (Bern 1994). 1997. PMID: 9432686 Review. German.
-
[The role of neoadjuvant therapy in the treatment of locally advanced, stage III non-small-cell lung cancer].Magy Onkol. 2005;49(2):161-8. Epub 2005 Oct 24. Magy Onkol. 2005. PMID: 16249813 Review. Hungarian.
Cited by
-
[Therapy-induced tumor regression and regression grading in lung cancer].Pathologe. 2014 Nov;35(6):574-7. doi: 10.1007/s00292-014-1919-x. Pathologe. 2014. PMID: 25319225 Review. German.
-
[Therapy-induced morphological changes in lung cancer].Pathologe. 2004 Nov;25(6):475-80. doi: 10.1007/s00292-004-0719-0. Pathologe. 2004. PMID: 15375632 German.
-
Defining response to radiotherapy in rectal cancer using magnetic resonance imaging and histopathological scales.World J Gastroenterol. 2016 Oct 7;22(37):8414-8434. doi: 10.3748/wjg.v22.i37.8414. World J Gastroenterol. 2016. PMID: 27729748 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical